Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03804840
Other study ID # AIS
Secondary ID
Status Completed
Phase Early Phase 1
First received
Last updated
Start date March 1, 2017
Est. completion date December 1, 2018

Study information

Verified date January 2019
Source University of Chicago
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Marijuana use, for both recreational and therapeutic purposes, is becoming increasingly common as states remove restrictions on use. The increased use raises new concern about the safety of this drug, including its ability to impair basic cognitive and psychomotor tasks, and whether the users are aware of their impairment. We propose to design a simple performance test that users can use in the field, using a cell phone, to assess their level of impairment relative to their own drug-free state. In this preliminary study, we will compare participants' simple task performance after a known dose of delta-9-tetrahydrocannabinol (THC), or placebo, administered under double-blind conditions. In our app the participants will be asked to gauge their own perceived level of impairment (as determined by self-ratings and judgments of impairment) as well as their actual impairment (as gauged by the app), providing important feedback and training about their ability to detect impairment.


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date December 1, 2018
Est. primary completion date December 1, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria:

1. 18-35 years old, males and females (N=44; 36 completers; 18 men, 18 women)

2. BMI 19-26

3. High school education, fluent in English

4. Experienced non-daily marijuana users

Exclusion Criteria:

5. Current drug/alcohol abuse or dependence

6. Past year drug/alcohol dependence

7. Diagnosis with drug treatment for psychosis/bipolar/schizophrenia

8. Past year major depression

9. Panic/anxiety attacks in past 2 months

10. PTSD

11. ADHD

12. Cardiovascular illness, high blood pressure, abnormal EKG

13. Current medications

14. Pregnant or planning to become pregnant

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Dronabinol
THC (Marinol® [dronabinol]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication (Broyd et al, 2016; Hartman and Huestis, 2013).
Placebo
Placebo

Locations

Country Name City State
United States University of Chicago Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
University of Chicago

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Simple Reaction Time In this reaction time task, the user is asked to shake the device in response to a visual clue on the device's screen. The user makes three attempts, in which he or she must shake or move the device with an acceleration that is greater than the value of the thresholdAcceleration property within the given time. The task finishes when the user successfully completes the attempts as instructed in the task. Data collected by this task is in the form of ORKReactionTimeResult objects. Each of these objects contain a timestamp representing the delivery of the stimulus and an ORKFileResult object that references the motion data collected during an attempt. Assessed two hour post intervention at peak effects